International reference: 3 US FDA recalls for this ingredient

Sub-Potent Drug: Subpotent assay results during stability testing. (proparacaine)

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared. (proparacaine)

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penici (proparacaine)

US-market enforcement records (OpenFDA), shown for reference - not specific to this product in Rwanda.

Registered Rwanda · Rwanda FDA

AUROCAINE

Proparacaine Hydrochloride Ophthalmic solution USP 0.5% w/v

Rwanda FDA-HMP-MA-0873 Ophthalmic Eye Drops 0.5% w/v INN generic

What it does

Proparacaine is a local anesthetic used to numb the eye for medical procedures.

Commonly used for: eye surgery, diagnostic eye tests

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
Rwanda FDA-HMP-MA-0873
Registration date
17/02/2024
Expiry date
16/02/2029
Status
Registered
Active ingredient
Proparacaine Hydrochloride Ophthalmic solution USP 0.5% w/v
Dosage form
Ophthalmic Eye Drops
Strength
0.5% w/v
Pack size
10 ml Bottle
Therapeutic class
-
Manufacturer / MAH
Aurolab
Applicant / LTR
AUROLAB
Country of origin
INDIA
Manufacturer location
No 1, Sivaganga Rd, Veerapanjan, Madurai, Tamil Nadu 625020, India

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:21 · updated 2026-09-21 02:30:20

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

Proparacaine is a local anesthetic used to numb the eye for medical procedures.

What it treats

  • eye surgery
  • diagnostic eye tests

How it works

Proparacaine blocks nerve signals in the area it is applied, which helps prevent pain during procedures.

Who it's for

Proparacaine is for people needing numbing of the eye for medical reasons.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: proparacaine

BNF-referenced

Proparacaine is a local anesthetic commonly used in ophthalmology for ocular procedures. It acts by blocking nerve impulses, providing temporary loss of sensation in the cornea and conjunctiva to facilitate various eye examinations and surgeries.

Indications

  • Ophthalmic procedures
  • Corneal anesthesia
  • Eye examinations

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Instill 1-2 drops into the affected eye(s) as needed, not exceeding 2-3 times per procedure.

Mechanism of action

The exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability through the lipid layer of the nerve cell membrane. Proparacaine may alter epithelial sodium channels through interaction with channel protein residues. This limitation prevents the fundamental change necessary for the generation of the action potential.

Pharmacodynamics

Proparacaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. More specifically, proparacaine appears to bind or antagonize the function of voltage gated sodium channels.

Pharmacokinetics

Proparacaine is rapidly absorbed through the corneal epithelium and has a quick onset of action, typically within 10-20 seconds of application. The duration of effect is usually around 15-30 minutes. Metabolism primarily occurs in the liver, and elimination is through renal excretion.

Adverse effects

  • Burning or stinging at the application site
  • Corneal epithelial toxicity
  • Allergic reactions
  • Systemic toxicity in cases of overdose

Precautions

  • Use with caution in patients with a history of hypersensitivity to local anesthetics
  • Monitor for signs of systemic absorption leading to CNS or cardiovascular toxicity

Pregnancy

Proparacaine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether proparacaine is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store at room temperature, away from light and moisture. Do not freeze.

Formulations

  • 0.5% ophthalmic solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: proparacaine

PubChem CID 4935

Molecular formula: C16H26N2O3

Mechanism of action

The exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability through the lipid layer of the nerve cell membrane. Proparacaine may alter epithelial sodium channels through interaction with channel protein residues. This limitation prevents the fundamental change necessary for the generation of the action potential.

Pharmacodynamics

Proparacaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. More specifically, proparacaine appears to bind or antagonize the function of voltage gated sodium channels.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.